Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Pattern Recognition of Immune Cells in Atopic Dermatitis Patients Receiving Dupilumab
Charite University, Berlin, Germany
25 participants
Oct 1, 2019
OBSERVATIONAL
Conditions
Summary
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05098821